LakeShore Biopharma Announces Transition to OTC Market Following Nasdaq Delisting

Stock Information for Bioxytran Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Bioxytran Inc

LakeShore Biopharma Announces Receipt of Delisting Determination Letter from Nasdaq
LakeShore Biopharma Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee
LakeShore Biopharma Announces Receipt of a Revised Preliminary Non-Binding Proposal to Acquire the Company and Formation of Special Committee
LakeShore Biopharma Announces Receipt of a Preliminary Non-Binding Proposal to Acquire the Company
LakeShore Biopharma Announces Fiscal Year 2025 Financial Results
LakeShore Biopharma Announces US$15 Million Private Placement Financing
LakeShore Biopharma Announces the Official Launch of a Novel Packaging Solution for YSJA(TM) Rabies Vaccine (Vero Cell)
LakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full-Year Guidance

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.